The company Haiku Houses designed the post-and-beam structure reminiscent of a 16th century Japanese country house.

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)’ base editing platform in sickle cell disease, or SCD, ...

Living Off The Land & Ocean in Remote Australia (Sharks, Swimming Holes & Ancient Art) (Ep9) Watch unbelievable moments as ...

Analysts estimate that Beam Therapeutics will report an earnings per share (EPS) of $-1.16. The announcement from Beam Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...